BT5528

DRUG2 trials

Sponsors

Bicycletx Limited, BicycleTx Limited

Conditions

Advanced Malignancies Associated with EphA2 ExpressionAdvanced Solid Tumor Historically Known for High EphA2 ExpressionGastric/Upper Gastrointestinal CancerHead and Neck CancerNon-small Cell Lung CancerOvarian CancerTriple Negative Breast CancerUrothelial Cancer

Phase 1

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Active, not recruitingNCT04180371

BicycleTx LimitedAdvanced Solid Tumor Historically Known for High EphA2 Expression, Gastric/Upper Gastrointestinal Cancer, Head and Neck Cancer +4

Start: 2019-11-07End: 2027-07-31Target: 288Updated: 2025-11-17

A Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression

RecruitingCTIS2024-510655-36-00

Bicycletx LimitedAdvanced Malignancies Associated with EphA2 Expression

Start: 2022-02-01Target: 63Updated: 2026-01-15

Related Papers

Abstract CT063: An EphA2-targeting Bicycle Drug Conjugate (BDC), BT5528, in combination with nivolumab in patients (pts) with advanced solid tumors: Results from a Phase 1/2 study

Cancer Research2026-04-17

Breaking from the paradigm of antibody-drug conjugates: Evaluation of clinical pharmacokinetics and safety of bicycle toxin conjugates (BTCs).

Journal of Clinical Oncology2024-06-013 citations

Abstract LB_A17: Trial in progress: First-in-human phase I dose-escalation study of a novel Bicycle toxin conjugate (BT5528) targeting EphA2 in patients with advanced solid tumors

Molecular Cancer Therapeutics2023-12-01

Abstract 1319: Rapid accumulation of cytotoxic payload in tumor tissue drives BT5528 activity in tumor models

Cancer Research2021-07-011 citations

BT5528-100 phase I/II study of the safety, pharmacokinetics, and preliminary clinical activity of BT5528 in patients with advanced malignancies associated with EphA2 expression.

Journal of Clinical Oncology2020-05-2016 citations